Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for cancer of unknown primary site has been reported in the published literature.
5 clinical trials registered, 1 recruiting. Interventions under study include other interventions, drug therapy, gene therapy, and procedural interventions. Pipeline includes 1 PHASE1, 2 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03740503](https://clinicaltrials.gov/study/NCT03740503) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 1:47 AM UTC
European rare disease database
Genomic Investigation of Unusual Responders |
— |
University Health Network, Toronto |
UNKNOWN |
[NCT07372963](https://clinicaltrials.gov/study/NCT07372963) | 18F-FAPI PET in Cancers of Unknown Primary Site | — | First Affiliated Hospital of Zhejiang University | NOT_YET_RECRUITING |
[NCT04459273](https://clinicaltrials.gov/study/NCT04459273) | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers | PHASE1 | Jonsson Comprehensive Cancer Center | UNKNOWN |
[NCT07366008](https://clinicaltrials.gov/study/NCT07366008) | The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP) | NA | Haukeland University Hospital | NOT_YET_RECRUITING |
[NCT04504604](https://clinicaltrials.gov/study/NCT04504604) | TCF-001 TRACK (Target Rare Cancer Knowledge) Study | NA | TargetCancer Foundation | RECRUITING |
15 publications have been identified in PubMed for cancer of unknown primary site. Research spans Review / Meta-Analysis (33%), Diagnostic / Biomarker (27%), and Case Report / Case Series (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 5 | 33% |
Testing and diagnosis research | 4 | 27% |
Patient case studies | 2 | 13% |
Disease patterns and progression | 2 | 13% |
Other research | 1 | 7% |
New treatment approaches | 1 | 7% |
Ilic I (2026). [PMID: 41873986](https://pubmed.ncbi.nlm.nih.gov/41873986/). *Epidemiologia (Basel)*. [Epidemiology / Natural History]
Komo T (2026). [PMID: 41685201](https://pubmed.ncbi.nlm.nih.gov/41685201/). *Surg Case Rep*. [Case Report / Case Series]
Bibas M (2025). [PMID: 40802957](https://pubmed.ncbi.nlm.nih.gov/40802957/). *The New England journal of medicine*. [Review / Meta-Analysis]
Piñol Ribas M (2025). [PMID: 39983334](https://pubmed.ncbi.nlm.nih.gov/39983334/). *Rev Esp Patol*. [Review / Meta-Analysis]
Bellanti JA (2025). [PMID: 40802958](https://pubmed.ncbi.nlm.nih.gov/40802958/). *The New England journal of medicine*. [Review / Meta-Analysis]
Raghav K (2025). [PMID: 40802959](https://pubmed.ncbi.nlm.nih.gov/40802959/). *N Engl J Med*. [Other]
Anthony Greco F (2025). [PMID: 40701441](https://pubmed.ncbi.nlm.nih.gov/40701441/). *Ann Oncol*. [Review / Meta-Analysis]
Brown M (2025). [PMID: 40027458](https://pubmed.ncbi.nlm.nih.gov/40027458/). *J Brown Hosp Med*. [Case Report / Case Series]
Dorobisz K (2025). [PMID: 41135818](https://pubmed.ncbi.nlm.nih.gov/41135818/). *Alcohol*. [Epidemiology / Natural History]
Raghav K (2025). [PMID: 40435465](https://pubmed.ncbi.nlm.nih.gov/40435465/). *The New England journal of medicine*. [Review / Meta-Analysis]
AI-curated news mentioning cancer of unknown primary site
Updated Aug 14, 2026
A recent study published in PubMed highlights molecular alterations in patients of color with advanced cutaneous and unknown primary melanomas. This research could inform targeted therapies and improve outcomes for these underrepresented populations.